Can ketamine help with fibromyalgia?

Yes. Research shows IV ketamine can reduce fibromyalgia pain by blocking the overactive NMDA receptors that drive central sensitization. A 2025 study of 53 fibromyalgia patients found that 41.5% achieved a complete response and an additional 15% achieved a partial response to IV ketamine treatment.

How does ketamine work differently than typical fibromyalgia medications?

Most fibromyalgia medications like pregabalin, duloxetine, and milnacipran work by modulating pain signals downstream. Ketamine addresses the root dysfunction by blocking NMDA receptors and the glutamate-driven central sensitization that keeps the nervous system stuck in a pain-amplifying state. It targets the mechanism that makes fibromyalgia self-perpetuating.

How long does ketamine relief last for fibromyalgia?

Duration varies by individual and protocol. Single low-dose infusions may provide hours to days of relief. Higher-dose multi-day protocols and maintenance infusions can extend benefits for weeks to months. Many patients find that periodic booster infusions help sustain their improvement over time.

Is IV ketamine safe for fibromyalgia patients?

Yes. IV ketamine has been studied in fibromyalgia patients across multiple clinical trials with a well-documented safety profile. Side effects are mild and temporary, typically including mild dissociation and possible nausea that resolve shortly after the infusion. At Music City Ketamine, Marla Peterson, CRNA, provides anesthesia-level monitoring throughout every session.

Do I need to stop my other fibromyalgia medications before ketamine therapy?

In most cases, no. Ketamine therapy is designed to work alongside your existing treatment plan, not replace it. During your consultation, we will review your current medications and discuss any adjustments that may be appropriate. Never stop or change medications without consulting your prescribing provider.

Ketamine for Fibromyalgia: How IV Therapy Addresses Central Sensitization

What Makes Fibromyalgia So Difficult to Treat

Fibromyalgia affects an estimated 4 million adults in the United States, roughly 2% of the adult population. The condition is defined by widespread musculoskeletal pain, fatigue, sleep disruption, and cognitive difficulties often called “fibro fog.” But the defining feature of fibromyalgia—the thing that makes it so resistant to treatment—is that the pain is not coming from damaged tissue. It is coming from a nervous system that has become stuck processing normal signals as painful ones.

This is a condition called central sensitization. In fibromyalgia, the spinal cord and brain amplify incoming sensory signals, lowering the threshold at which stimuli register as painful. Touch that should feel neutral hurts. Pressure that should feel mild becomes excruciating. The volume knob on pain processing has been turned up, and conventional treatments struggle to turn it back down.

The FDA has approved three medications for fibromyalgia: pregabalin (Lyrica), duloxetine (Cymbalta), and milnacipran (Savella). Each helps some patients, but the response rates are modest. Clinical trials show that roughly 30% of patients achieve meaningful relief from these medications, and many stop taking them within the first year due to side effects or diminishing benefits. For the majority, the search for something that works continues.

This is where the mechanism of fibromyalgia becomes clinically important. If the core problem is NMDA receptor-driven central sensitization, then a treatment that directly addresses NMDA receptor dysfunction has a logical basis that downstream symptom management does not.

The NMDA Connection: Why Fibromyalgia Responds to Ketamine

The relationship between NMDA receptors and fibromyalgia is well established in the pain research literature. A study published in Biomedicines found that NMDA receptor overactivation is a primary driver of the central sensitization seen in fibromyalgia. Glutamate, the brain’s main excitatory neurotransmitter, binds to these receptors and triggers a cascade of increased pain sensitivity at the spinal cord and brain level.

In a healthy nervous system, this process has a natural off-switch. In fibromyalgia, the off-switch is broken. NMDA receptors remain in a state of heightened activity, creating what researchers call “wind-up”—a progressive increase in pain signaling where each stimulus builds on the last. Over months and years, this wind-up becomes self-sustaining. The nervous system rewires itself around pain.

Ketamine is an NMDA receptor antagonist. It binds to the channel inside the NMDA receptor and physically blocks it, reducing the receptor’s ability to pass excitatory signals. In the context of fibromyalgia, this means ketamine can interrupt the wind-up process at its source.

Several specific mechanisms are at work:

Blocking wind-up. By preventing NMDA receptors from sustaining the escalating pain cascade, ketamine can interrupt the cycle that keeps fibromyalgia pain self-perpetuating.
Reducing central sensitization. Ketamine modulates the heightened excitability in spinal cord and brainstem pain pathways, effectively recalibrating the nervous system’s pain threshold closer to normal.
Altering pain memory. Research published in The Journal of Pain suggests that ketamine can modify the way the nervous system stores and recalls pain patterns—a process that is particularly relevant in fibromyalgia, where the brain has essentially learned to produce pain in the absence of tissue damage.
Promoting neuroplasticity. Beyond acute pain relief, ketamine stimulates the growth of new synaptic connections, which may help the brain form healthier neural pathways that are not organized around chronic pain.
Addressing co-occurring depression. Fibromyalgia and depression frequently travel together—estimates suggest that 40% to 80% of fibromyalgia patients also meet criteria for major depressive disorder. Ketamine is one of the few treatments that can meaningfully address both conditions through a single mechanism, acting on the glutamate system that underlies both pain sensitization and mood regulation.

This is not a theoretical argument. The NMDA receptor’s role in fibromyalgia is supported by studies showing that other NMDA-modulating drugs, like memantine, also reduce fibromyalgia symptoms. Ketamine is the most potent and well-studied NMDA antagonist available in clinical medicine, and its effects on this receptor system are well characterized after more than 50 years of use.

What the Clinical Data Shows

The evidence base for ketamine in fibromyalgia has been growing, with several studies now providing concrete outcome data.

A 2025 retrospective study published in the Journal of Pain & Palliative Care Pharmacotherapy evaluated 53 fibromyalgia patients who underwent a three-day IV ketamine induction protocol at 1.44 mg/kg/day. The results broke down into three groups:

41.5% were complete responders—meaning they achieved clinically significant pain reduction
15% were partial responders—reporting meaningful but incomplete improvement
43.5% were non-responders—not achieving meaningful pain relief

That 56.5% of patients experienced at least partial benefit is notable for a population that, by definition, has already tried and failed multiple other treatments. The study also tracked safety outcomes: significant adverse events occurred in only two patients (3.8%), both of which were cardiovascular and resolved with standard management.

A 2024 systematic review published in Advances in Rheumatology analyzed six studies encompassing 115 fibromyalgia patients treated with IV ketamine. The review found:

Pain scores on a visual analog scale dropped from a range of 59–100 mm before treatment to 2–95 mm after treatment
Most studies using short-term protocols showed a good response
Side effects were common but mild, appearing during the infusion and resolving within minutes of completion

The review also noted that higher doses and more frequent infusion protocols appeared to produce greater and longer-lasting pain reduction, though more research is needed to establish optimal dosing guidelines for fibromyalgia specifically.

NMDA receptor-related pain mechanisms may be dominant in a subset of fibromyalgia patients, and this subset may be the group most likely to respond to ketamine therapy. Identifying these patients through clinical assessment is an important part of treatment planning. — Based on Biomedicines, 2017; Advances in Rheumatology, 2024

A case report published in Pain Medicine (2023) documented a fibromyalgia patient who achieved sustained improvement with periodic maintenance infusions over 19 months, suggesting that ongoing treatment can help maintain benefits for the subset of patients who respond well to the initial protocol.

How Ketamine Compares to Standard Fibromyalgia Treatments

To put the ketamine data in context, it helps to compare it against the medications currently approved for fibromyalgia.

Pregabalin (Lyrica) works by reducing the release of several neurotransmitters, including glutamate. It addresses part of the same pathway ketamine targets, but less directly. Clinical trials show a 30% responder rate, and common side effects include dizziness, weight gain, and cognitive dulling that can worsen fibro fog.

Duloxetine (Cymbalta) is an SNRI antidepressant that modulates serotonin and norepinephrine in descending pain inhibition pathways. Response rates are similar to pregabalin, around 30%. Side effects include nausea, dry mouth, and sexual dysfunction.

Milnacipran (Savella) is another SNRI with a slightly different pharmacological profile. Its response rates and side effect profile are comparable to duloxetine.

None of these medications directly block NMDA receptors or address the wind-up phenomenon that drives central sensitization. They work downstream of the core problem. This is likely why their response rates plateau at around 30% and why many patients find their benefits diminish over time.

Ketamine, by directly blocking the NMDA receptor, addresses the mechanism that these other treatments leave in place. It is not a replacement for these medications—some patients benefit from combination approaches—but it offers a fundamentally different angle of treatment for patients who have not found adequate relief through conventional options.

Who Might Be a Good Candidate

Ketamine for fibromyalgia is not appropriate for everyone with the diagnosis. Based on the available evidence and our clinical experience with chronic pain patients, the strongest candidates tend to be:

Patients who have tried FDA-approved fibromyalgia medications without adequate relief. If pregabalin, duloxetine, or milnacipran have not worked or have produced intolerable side effects, ketamine offers a genuinely different mechanism.
Patients with prominent features of central sensitization. If you experience widespread pain sensitivity, allodynia (pain from normally non-painful touch), or pain that seems disproportionate to any identifiable physical cause, the NMDA-mediated mechanism of ketamine may be particularly relevant to your situation.
Patients dealing with fibromyalgia and co-occurring depression or anxiety. The overlap between fibromyalgia and mood disorders is substantial. Ketamine’s ability to address both pain and depressive symptoms through the same glutamate pathway makes it uniquely suited for patients carrying both burdens.
Patients who want to reduce their reliance on opioids. Some fibromyalgia patients end up on chronic opioid therapy despite guidelines recommending against it. Ketamine provides potent pain relief through a non-opioid, non-addictive mechanism.

What to Expect at Music City Ketamine

If you are considering ketamine therapy for fibromyalgia, the process begins with a thorough consultation. We will review your diagnosis, treatment history, current medications, and symptom profile to determine whether ketamine is a reasonable option for your specific situation.

For chronic pain protocols, the dosing and timing may differ from what we use for mental wellness conditions. Your treatment plan will be individualized based on your clinical needs. Marla Peterson, CRNA, administers and monitors every session directly, using the same monitoring equipment and protocols described in our safety overview—continuous pulse oximetry, blood pressure, and heart rate tracking throughout.

The treatment environment is designed to be calming. Private rooms, comfortable recliners, and our therapy dogs Walter White and Wilma create an atmosphere that is closer to a high-end wellness space than a hospital infusion center. Many patients find the environment itself therapeutic, especially after years of rotating through clinical settings that have not provided relief.

You will need a driver for each session. Most patients are able to resume normal activities the following day.

Honest Expectations

We want to be straightforward about what ketamine can and cannot do for fibromyalgia at this stage of the evidence.

Not everyone responds. The 2025 study found that 43.5% of patients were non-responders. Fibromyalgia is a heterogeneous condition, and NMDA-driven central sensitization may not be the dominant mechanism in every patient. We cannot predict with certainty who will respond and who will not.
The research is still developing. While the available data is consistently positive for responders, more large-scale randomized controlled trials are needed to establish definitive dosing guidelines and identify which fibromyalgia subtypes respond best.
Maintenance treatment may be needed. Like many chronic pain treatments, ketamine’s benefits for fibromyalgia may require periodic booster sessions to sustain. The optimal maintenance schedule is still being defined in the research literature.
Ketamine works alongside existing care, not instead of it. Physical therapy, sleep hygiene, stress management, and other components of fibromyalgia treatment remain important. Ketamine addresses one critical piece of the puzzle—central sensitization—but it does not eliminate the need for a comprehensive approach.
Insurance typically does not cover ketamine for fibromyalgia. As with other off-label uses, IV ketamine for fibromyalgia is a self-pay treatment. At Music City Ketamine, sessions are $475 each. We are transparent about costs from the beginning.

The question worth asking is whether a treatment that directly targets the NMDA receptor dysfunction at the heart of fibromyalgia deserves consideration after other approaches have fallen short. For the 56.5% of patients in the 2025 study who achieved at least partial response, the answer was yes.